Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ
Market Cap
$954.37M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
231 of 809
Rank in Industry
138 of 445
Largest Insider Buys in Sector
TARS Stock Price History Chart
TARS Stock Performance
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Insider Activity of Tarsus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Tarsus Pharmaceuticals, Inc. have bought $178,661 and sold $5.3M worth of Tarsus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Tarsus Pharmaceuticals, Inc. have bought $8.14M and sold $15.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lin Elizabeth Yeu (director) — $319,402. Goldberg Andrew D. (director) — $18,960.
The last purchase of 1,000 shares for transaction amount of $18,960 was made by Goldberg Andrew D. (director) on 2023‑12‑15.
List of Insider Buy and Sell Transactions, Tarsus Pharmaceuticals, Inc.
| 2024-06-18 | Sale | Farrow Jeffrey S | See Remarks | 10,445 0.0233% | $27.47 | $286,924 | -3.79% | |
| 2024-03-18 | Sale | Neervannan Seshadri | Chief Operating Officer | 4,879 0.013% | $30.60 | $149,297 | +11.67% | |
| 2024-03-18 | Sale | Mottiwala Aziz | Chief Commercial Officer | 4,766 0.0127% | $30.60 | $145,840 | +11.67% | |
| 2024-03-18 | Sale | Wahl Bryan | General Counsel | 4,436 0.0118% | $30.60 | $135,742 | +11.67% | |
| 2024-03-18 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 4,314 0.0115% | $30.60 | $132,008 | +11.67% | |
| 2024-03-18 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 10,415 0.0278% | $30.60 | $318,699 | +11.67% | |
| 2023-12-27 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,000 0.024% | $20.22 | $161,760 | +59.52% | |
| 2023-12-20 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 40,000 0.1223% | $20.27 | $810,623 | +60.81% | |
| 2023-12-20 | Sale | Trevejo Jose M. | CHIEF MEDICAL OFFICER | 2,252 0.0068% | $20.00 | $45,040 | +60.81% | |
| 2023-12-15 | Goldberg Andrew D. | director | 1,000 0.003% | $18.96 | $18,960 | +69.16% | ||
| 2023-11-30 | Sale | Wahl Bryan | General Counsel | 8,356 0.025% | $16.31 | $136,286 | +91.86% | |
| 2023-11-30 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 8,355 0.025% | $16.31 | $136,270 | +91.86% | |
| 2023-11-15 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,000 0.0252% | $18.37 | $146,933 | +74.64% | |
| 2023-10-18 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,000 0.0245% | $13.24 | $105,920 | +128.72% | |
| 2023-10-05 | Sale | Trevejo Jose M. | CHIEF MEDICAL OFFICER | 1,604 0.0051% | $18.00 | $28,872 | +59.42% | |
| 2023-09-20 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,000 0.0252% | $17.21 | $137,680 | +67.61% | |
| 2023-08-23 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,000 0.0244% | $17.23 | $137,840 | +48.79% | |
| 2023-08-15 | Lin Elizabeth Yeu | director | 9,506 0.035% | $16.80 | $159,701 | +43.24% | ||
| 2023-07-19 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 103,900 0.3866% | $20.01 | $2.08M | +9.60% | |
| 2023-07-19 | Sale | Mottiwala Aziz | Chief Commercial Officer | 2,400 0.0089% | $20.05 | $48,120 | +9.60% |
Insider Historical Profitability
28.73%
| Azamian Bobak R. | President/CEO and Board Chair | 26456 2.5075% | $25.26 | 0 | 56 | |
| Neervannan Seshadri | Chief Operating Officer | 64767 0.1652% | $25.26 | 0 | 7 | |
| Mottiwala Aziz | Chief Commercial Officer | 54075 0.1384% | $25.26 | 0 | 17 | |
| Wahl Bryan | General Counsel | 40951 0.0966% | $25.26 | 0 | 11 | |
| Whitfield Dianne C. | Chief Human Resources Officer | 34181 0.0809% | $25.26 | 0 | 11 | |
| Farrow Jeffrey S | See Remarks | 18136 0.048% | $25.26 | 0 | 1 | |
| Lin Elizabeth Yeu | director | 15866 0.0479% | $25.26 | 2 | 0 | <0.0001% |
| Goldberg Andrew D. | director | 3000 0.0091% | $25.26 | 1 | 0 | |
| Trevejo Jose M. | CHIEF MEDICAL OFFICER | 2251 0.0068% | $25.26 | 0 | 8 | |
| Vivo Capital IX, LLC | 10 percent owner | 2469001 7.4582% | $25.26 | 1 | 10 | +36.85% |
| Vivo Capital Fund IX, L.P. | 2469001 7.4582% | $25.26 | 0 | 2 | ||
| RTW INVESTMENTS, LP | 10 percent owner | 2013601 6.0825% | $25.26 | 0 | 1 | |
| Tester Jason E. | 1920933 5.8026% | $25.26 | 1 | 0 | +36.85% | |
| Horowitz Limited Partnership VIII | 10 percent owner | 1920933 5.8026% | $25.26 | 1 | 0 | +36.85% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 1917157 5.7912% | $25.26 | 1 | 0 | +36.85% |
| Ackermann Michael | 100000 0.3021% | $25.26 | 1 | 9 | +25.23% | |
| Greenstein Leonard M. | Chief Financial Officer | 26785 0.0809% | $25.26 | 0 | 14 | |
| Holdbrook Mark J. | V.P., Clinical Affairs | 3191 0.0096% | $25.26 | 0 | 3 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RTW Investments, LP | $118.95M | 8.66 | 3.27M | +3.81% | +$4.36M | 1.76 | |
| Paradigm BioCapital Advisors LP | $104.08M | 7.58 | 2.86M | +179.36% | +$66.83M | 3.78 | |
| BlackRock | $96.42M | 7.02 | 2.65M | +5.43% | +$4.96M | <0.01 | |
| Morgan Stanley | $87.2M | 6.35 | 2.4M | +22.54% | +$16.04M | 0.01 | |
| Tang Capital Management, LLC | $81.96M | 5.97 | 2.25M | +2.27% | +$1.82M | 0.32 | |
| Cormorant Asset Management Lp | $77.76M | 5.66 | 2.14M | -3.71% | -$2.99M | 3.69 | |
| Cowen Group | $77.15M | 5.62 | 2.12M | +11.05% | +$7.67M | 2.45 | |
| The Vanguard Group | $66.4M | 4.84 | 1.83M | +14.49% | +$8.4M | <0.01 | |
| Frazier Life Sciences Management L P | $64.98M | 4.73 | 1.79M | 0% | +$0 | 3.34 | |
| JENNISON ASSOCIATES LLC | $48.38M | 3.52 | 1.33M | New | +$48.38M | 0.03 | |
| Perceptive Advisors | $47.12M | 3.43 | 1.3M | 0% | +$0 | 0.03 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $32.64M | 2.38 | 898,000 | +1,113.51% | +$29.95M | 0.11 | |
| Tcg Crossover Management Llc | $28.86M | 2.1 | 793,829 | -30.54% | -$12.69M | 0.05 | |
| Ensign Peak Advisors Inc | $26.46M | 1.93 | 727,891 | +66.23% | +$10.54M | 0.05 | |
| State Street | $26.07M | 1.9 | 717,090 | +6.26% | +$1.54M | <0.01 | |
| Ikarian Capital LLC | $25.82M | 1.88 | 710,277 | +36.98% | +$6.97M | 7.37 | |
| Geode Capital Management | $22.89M | 1.67 | 629,692 | +3.27% | +$725,503.12 | <0.01 | |
| Artisan Partners | $22.81M | 1.66 | 627,430 | +60.88% | +$8.63M | 0.03 | |
| Boone Capital Management Llc | $22.14M | 1.61 | 609,104 | New | +$22.14M | 4.48 | |
| Integral Health Asset Management Llc | $21.45M | 1.56 | 590,000 | +490% | +$17.81M | 2.12 | |
| Vivo Capital | $20.56M | 1.5 | 565,550 | -68.3% | -$44.29M | 1.81 | |
| Tfg Asset Management Gp Ltd | $16.36M | 1.19 | 450,000 | -43.75% | -$12.72M | 8.62 | |
| Dimensional Fund Advisors | $15.44M | 1.12 | 424,830 | -1.23% | -$192,545.94 | <0.01 | |
| T. Rowe Price | $12.64M | 0.92 | 347,683 | New | +$12.64M | <0.01 | |
| GHOST TREE CAPITAL LLC | $10.9M | 0.79 | 300,000 | 0% | +$0 | 3.54 | |
| Walleye Capital | $9.91M | 0.72 | 272,498 | New | +$9.91M | 0.03 | |
| Jefferies Financial Group | $9.84M | 0.72 | 270,758 | -28.89% | -$4M | 0.18 | |
| Northern Trust | $8.98M | 0.65 | 247,177 | -0.63% | -$57,178.55 | <0.01 | |
| Bank of America | $8.34M | 0.61 | 229,492 | -3.91% | -$339,181.88 | <0.01 | |
| Invesco | $8.13M | 0.59 | 223,569 | +128.43% | +$4.57M | <0.01 | |
| Charles Schwab | $8.07M | 0.59 | 221,997 | +1.52% | +$121,227.25 | <0.01 | |
| Citadel Advisors LLC | $7.97M | 0.58 | 219,278 | +409.51% | +$6.41M | 0.01 | |
| ExodusPoint Capital Management, LP | $7.85M | 0.57 | 215,958 | -7.27% | -$615,835.95 | 0.1 | |
| Goldman Sachs | $7.41M | 0.54 | 203,730 | -14.2% | -$1.23M | <0.01 | |
| D. E. Shaw & Co. | $7.14M | 0.52 | 196,512 | +384.89% | +$5.67M | 0.01 | |
| Allspring Global Investments | $6.99M | 0.51 | 192,303 | +2.61% | +$177,715.15 | 0.01 | |
| Boothbay Fund Management LLC | $6.38M | 0.47 | 175,512 | +57.03% | +$2.32M | 0.21 | |
| Sands Capital Ventures LLC | $6.18M | 0.45 | 170,000 | -34.62% | -$3.27M | 1.49 | |
| J. Goldman & Company | $5.94M | 0.43 | 163,347 | +125.79% | +$3.31M | 0.27 | |
| Driehaus Capital Management LLC | $5.86M | 0.43 | 161,163 | New | +$5.86M | 0.06 | |
| Nuveen | $5.7M | 0.42 | 156,787 | -33.69% | -$2.9M | <0.01 | |
| Nantahala Capital Management Llc | $5.46M | 0.4 | 150,321 | -59.94% | -$8.18M | 0.56 | |
| CIBC World Markets | $5.45M | 0.4 | 150,000 | New | +$5.45M | 0.01 | |
| Cibc World Markets Corp | $5.45M | 0.4 | 150,000 | New | +$5.45M | 0.04 | |
| Macquarie Group | $5.45M | 0.4 | 150,000 | 0% | +$0 | <0.01 | |
| Two Sigma | $5.37M | 0.39 | 147,826 | +105.48% | +$2.76M | 0.01 | |
| Baird Financial Group Inc | $4.66M | 0.34 | 128,272 | New | +$4.66M | 0.01 | |
| Wellington Management Company | $4.05M | 0.3 | 111,422 | New | +$4.05M | <0.01 | |
| Eam Investors | $3.66M | 0.27 | 100,658 | New | +$3.66M | 0.57 | |
| Laurion Capital Management LP | $3.63M | 0.27 | 100,000 | New | +$3.63M | 0.1 |